Reagents News and Research

RSS

The Native Antigen Company announces custom contract service to develop influenza A and B antigens

The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the introduction of its custom contract service to rapidly develop antigen panels for influenza A and B viruses.

21 Aug 2020

Avacta expands multi-target collaboration with LG Chem Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, to include new programs incorporating Avacta’s Affimer XT serum half-life extension system.

From Avacta Life Sciences Ltd. 21 Aug 2020

Absolute Antibody offers SARS-CoV-2 neutralizing antibodies derived from COVID-19 patients

Absolute Antibody Ltd. today announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19.

From Absolute Antibody Ltd 18 Aug 2020

FDA grants emergency use authorization to Yale's SalivaDirect COVID-19 diagnostic test

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Yale School of Public Health for its SalivaDirect COVID-19 diagnostic test, which uses a new method of processing saliva samples when testing for COVID-19 infection.

15 Aug 2020

Portable testing laboratory screens millions of bacteria in water samples

A suitcase-size portable testing laboratory could cut back the time and money spent on monitoring water quality in developing countries.

14 Aug 2020

New test allows rapid COVID-19 diagnosis

Researchers have developed a new test that can diagnose COVID-19 in just 20 minutes. The findings, published in the Journal of Medical Microbiology, show the rapid molecular test called N1-STOP-LAMP, is 100% accurate in diagnosing samples containing SARS-CoV-2 at high loads.

13 Aug 2020

Promega introduces new serological antibody test for COVID-19

Promega Corporation today announced the launch of its new serological antibody test for COVID-19 to detect the presence of antibodies against the SARS-CoV-2 virus.

From Promega Corporation 13 Aug 2020

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate effect. Neil will be responsible for late stage pre-clinical and early clinical development of Avacta’s pipeline of pre|CISION pro-drugs and Affimer immunotherapies.

From Avacta Life Sciences Ltd. 13 Aug 2020

A fast, economical method to detect SARS-CoV-2 virus in untreated wastewater

A group of researchers have demonstrated that, from seven methods commonly used to test for viruses in untreated wastewater, an adsorption-extraction technique can most efficiently detect SARS-CoV-2. This gives us another tool to detect the presence and spread of the COVID-19 pandemic.

12 Aug 2020

Scientists design new catalyst to widen the range of target chemical substances for radical reactions

Organocatalysts consisting of organic compounds without metal elements are receiving much attention as next generation catalysts in the hope of reducing environmental burden and coping with exhaustion/rising prices of rare metals.

12 Aug 2020

Mass spectrometry shows potential for rapid SARS-CoV-2 detection

A team from SPI in Marcoule detected by mass spectrometry, in 3 minutes and without specific reagents, signature peptides of the SARS-CoV-2 virus in clinical samples. It thus provides a proof of concept of the use of this method as a possible alternative to PCR, currently the reference method.

10 Aug 2020

Avacta appoints COVID-19 rapid antigen test manufacturing partner

Avacta Group plc is pleased to announce that it has appointed BBI Solutions to manufacture the saliva-based rapid SARS-CoV-2 antigen test.

From Avacta Life Sciences Ltd. 6 Aug 2020

Cytiva licenses advanced machine learning technology from Allen Institute

Cytiva and the Allen Institute have entered into a license agreement to integrate the Allen Institute's machine learning technology with Cytiva's microscopy and image analysis systems to advance the development of cell imaging innovations.

From Cytiva Life Sciences 6 Aug 2020

Fast, cheap and easy COVID-19 test from Yale

As a result, a new study by Yale University researchers and published on the preprint server medRxiv in August 2020 shows that a new saliva test named SalivaDirect simplifies the test approach, avoids invasive samples collection, and the need for trained personnel to collect specimens.

6 Aug 2020

A SARS-CoV-2 assay using plant proteins

Researchers in South Africa have developed a serological assay that readily detects antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using recombinant viral proteins produced in plants.

5 Aug 2020

New research project receives federal funding to expand treatment options for sickle cell patients

A new research project that could impact and expand the discovery of new treatment options for sickle cell patients has received significant federal funding.

5 Aug 2020

Researchers develop a redox potential-controlled, cost-effective chemical production method

A team of researchers from Japan has demonstrated a light-based reaction that yields high numbers of the base chemical component required to produce bioactive compounds used in common industry products.

3 Aug 2020

Analysis: When is a coronavirus test not a coronavirus test?

Desperate to continue the tradition of a family beach week, I hatched a plan that would allow some mask- and sanitizer-enhanced semblance of normality.

29 Jul 2020

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics.